Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Total Current Assets

All assets expected to be converted to cash or used up within one year.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets rises 15.8% from a year ago

Total current assets stood at $544.92M at the end of Q1 FY2026, up 15.8% from a year earlier and up 29.1% from the prior quarter. Over 3 fiscal years it compounded at +339.1% a year.

Context

  • Total current assets amounted to 98.4% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total current assets increased in 2 of the last 3 fiscal years.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +15.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$544.92M+29.1% QoQ
Last fiscal yearDec 2025
$422.05M-16.0% YoY
Year agoMar 2025
$470.75M+15.8% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%——
1 year-16.0%——
3-year CAGR+339.1%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
422.05M USD
Year-over-year change
-16.0%
3-year CAGR
+339.1%

Total Current Assets vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's Mar 2026 total current assets of $544.92M is the highest of the 6 companies compared; the peer median is $195.56M.
  • Its year-over-year change of +15.8% is the 3rd highest of 6, against a peer median of +13.7%.
  • Total current assets amounts to 98.4% of total assets for BCAX, versus a peer median of 95.4%.
BCAX Competitors Peer median
Total Current Assets for BCAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BCAXBicara Therapeutics Inc. Common StockMar 2026$544.92M +15.8%+339.1%98.4%
CGEMCullinan Therapeutics, Inc.Mar 2026$361.41M +13.7%-6.6%89.7%
CMPXCompass Therapeutics, Inc.Mar 2026$195.69M +57.6%+2.5%95.4%
CBIOCrescent Biopharma, Inc.Mar 2026$195.56M +3163.6%+67.1%98.2%
MGNXMacroGenics, Inc.Mar 2026$182.52M +0.2%-0.3%83.8%
CNTXContext Therapeutics Inc.Mar 2026$58.52M -36.9%+21.8%99.4%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $195.56M+13.7%+2.5%95.4%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.16M230.44M489.71M96.69M
Short-term Investments000318.12M
Net Receivables0000
Inventory0000
Other Current Assets68K100K12.82M7.25M
Total Current Assets4.98M231.07M502.53M422.05M
Property, Plant & Equipment (Net)636K815K845K2.03M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0059.2M0
Other Non-current Assets1.08M2.09M6.62M6.91M
Total Non-current Assets1.72M2.91M66.66M8.94M
Total Assets6.7M233.98M569.2M430.99M
Account Payables5.14M3.19M4.51M5.52M
Short-term Debt00607K0
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities009.79M22.32M
Total Current Liabilities23.9M15.09M17.99M28.95M
Long-term Debt0000
Deferred Tax Liabilities0059.2M0
Deferred Revenue (Non-current)0000
Other Non-current Liabilities85K17K00
Total Non-current Liabilities85K389K59.33M593K
Total Liabilities23.98M15.47M77.32M29.54M
Common Stock2K2K7K7K
Retained Earnings(101.04M)(153.02M)(221.02M)(358.97M)
Accumulated OCI000243K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(17.28M)218.51M491.88M401.45M
Total Debt0657K738K1.71M
Net Debt(4.16M)(229.78M)(488.97M)(94.98M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.